

**REMARKS**


The specification has been amended to provide a cross-reference to the previously filed International Application. The claims have also been amended to delete multiple dependencies and to place the application into better form for examination. Entry of the present amendment and favorable action on the above-identified application are earnestly solicited.

Attached hereto is a marked-up copy of the changes made to the application by this Amendment.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By   
Marc S. Weiner, #32,181

MSW/cqc  
0020-4841P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Attachment: Version With Markings Showing Changes Made

(Rev. 01/22/01)

09806568-073001

**VERSION WITH MARKINGS SHOWING CHANGES MADE**

The title has been amended as follows:

ENZYME PRODUCING PLASMA PROTEIN FRAGMENT HAVING INHIBITORY  
ACTIVITY TO METASTASIS AND GROWTH OF CANCER AND PLASMA PROTEIN  
FRAGMENT PRODUCED BY FRAGMENTATION BY SAID ENZYME [TECHNICAL  
FIELD]

The specification has been amended to provide cross-  
referencing to the International Application.

The claims have been amended as follows:

4. (Amended) The enzyme that produces plasma protein  
fragments of [any of claims 1 to 3]claim 1 wherein said enzyme  
cleaves plasminogen at 73L-74F and/or 451L-452P to produce  
fragments comprising Kringles 1 to 4 of plasminogen.

5. (Amended) Plasma protein fragments that are produced from  
degradation by the action of the enzyme that produces plasma  
protein fragments as set forth in [any of claims 1 to 4]claim 1  
and have an inhibitory activity to metastasis and growth of  
cancer.

9. (Amended) A process for preparing plasma protein  
fragments having an inhibitory activity of metastasis and growth  
of cancer, which comprises reacting plasma protein fragments as  
set forth in [any of claims 1 to 4]claim 1.

11. (Amended) A medicament for treating and preventing disease conditions associated with vascularization such as cancer (solid cancer), diabetic retinosis and rheumatism comprising as a major ingredient the enzyme that produces plasma protein fragments as set forth in [any of claims 1 to 4]claim 1.

12. (Amended) A medicament for treating and preventing cancer comprising as a major ingredient the enzyme that produces plasma protein fragments as set forth in [any of claims 1 to 4]claim 1.

13. (Amended) A medicament for treating and preventing disease conditions associated with vascularization such as cancer (solid cancer), diabetic retinosis and rheumatism comprising as a major ingredient the plasma protein fragments as set forth in [any of claims 5 to 8]claim 5.

14. (Amended) A medicament for treating and preventing cancer comprising as a major ingredient the plasma protein fragments as set forth in [any of claims 5 to 8]claim 5.